NFE2L2 and metabolic dysfunction-associated steatotic liver disease: Therefore, we sought to explore novel therapeutic approaches that enable activation of NRF2 selectively in the liver to target the pathological triggers of NAFLD and NASH without initiating off-target tissue effects.